Retatrutide's Double Trial, Appendicitis Delays, and the World's Heart Failure Toll

A daily look at new medical research for clinicians and curious listeners. Today we cover two phase three trials of the triple-hormone obesity drug retatrutide, a forty five thousand patient global study on appendicitis timing, and a sweeping analysis of heart failure worldwide. We also look at gut bacteria's surprising influence on CAR T cell cancer therapy and how immune cells inside pancreatic tumors protect cancer cells from dying.